{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:41:13Z","timestamp":1784302873700,"version":"3.55.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Idiopathic Multicentric Castleman Disease (iMCD) is a polyclonal lymphoproliferative disorder involving cytokine storms that can lead to organ failure and death. The cause of iMCD is unknown, but some clinical evidence suggests an autoimmune etiology. For example, connective tissue disorders (CTDs) and iMCD share many clinical features, and autoantibodies have been anecdotally reported in individual iMCD patients. This study investigates whether common autoantibodies are shared across iMCD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We assembled custom bead-based protein arrays consisting of 52 autoantigens traditionally associated with CTDs and 38 full-length cytokines and screened serum samples from 101 iMCD patients for IgG autoantibodies. We also screened samples with a 1,103-plex array of recombinant human protein fragments to identify additional autoantibody targets. Finally, we performed receptor blocking assays on select samples with anti-cytokine autoantibodies (ACAs) identified by array.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that an increased proportion of iMCD patients (47%) tested positive for at least one CTD-associated autoantibody compared to healthy controls (HC) (17%). Commonly detected CTD-associated autoantibodies were associated with myositis and overlap syndromes as well as systemic lupus erythematosus (SLE) and Sj\u00f6gren\u2019s Syndrome (SS). ACAs were also detected in a greater proportion of iMCD patients (38%) compared to HC (10%), while the protein fragment array identified a variety of other autoantibody targets. One iMCD sample tested positive for receptor blocking against interferon-\u03c9 (IFN\u03c9).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>IgG autoantibodies binding autoantigens associated with common CTDs and cytokines are elevated in iMCD patients compared to HC, suggesting that autoimmunity may be involved in iMCD pathogenesis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1528465","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T07:05:58Z","timestamp":1741849558000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric castleman disease patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Allan","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael V.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muge","family":"Kalaycioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Mumau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saishravan","family":"Shyamsundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateo Sarmiento","family":"Bustamante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaurya","family":"Dhingra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea","family":"Dodig-Crnkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen M.","family":"Schwenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Yoshizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fajgenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Utz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-545087","article-title":"HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy","volume":"123","author":"Fajgenbaum","year":"2014","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000931","article-title":"Overview of castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"10301","DOI":"10.3390\/ijms231810301","article-title":"Idiopathic plasmacytic lymphadenopathy forms an independent subtype of idiopathic multicentric castleman disease","volume":"23","author":"Nishikori","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218660","article-title":"Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease","volume":"14","author":"Nabel","year":"2019","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00317-7","article-title":"Castleman disease","volume":"7","author":"Carbone","year":"2021","journal-title":"Nat Rev Dis Primer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03494-2","article-title":"Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases","volume":"147","author":"Sun","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1186\/s12882-020-02191-z","article-title":"Idiopathic multicentric Castleman disease with Sj\u00f6gren\u2019s syndrome and secondary membranous nephropathy: a case report and review of the literature","volume":"21","author":"Pan","year":"2020","journal-title":"BMC Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2021.1947591","article-title":"A rare case of idiopathic multicentric Castleman disease in a patient with long-standing systemic autoimmunity","volume":"51","author":"Saleh","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2989-19","article-title":"Idiopathic multicentric castleman disease with autoimmune hemolytic anemia and production of anti-drug antibody against tocilizumab","volume":"58","author":"Tabata","year":"2019","journal-title":"Intern Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)00006-5","article-title":"Idiopathic multicentric Castleman\u2019s disease: a systematic literature review","volume":"3","author":"Liu","year":"2016","journal-title":"Lancet Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.135031","article-title":"Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease","volume":"5","author":"Pai","year":"2020","journal-title":"JCI Insight"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70231","article-title":"Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus","volume":"123","author":"Price","year":"2013","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1038\/s41467-021-25509-3","article-title":"New-onset IgG autoantibodies in hospitalized patients with COVID-19","volume":"12","author":"Chang","year":"2021","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1518553113","article-title":"Anoctamin 2 identified as an autoimmune target in multiple sclerosis","volume":"113","author":"Ayoglu","year":"2016","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aav6778","article-title":"AIRE expression controls the peripheral selection of autoreactive B cells","volume":"4","author":"Sng","year":"2019","journal-title":"Sci Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80477","article-title":"Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency","volume":"125","author":"Walter","year":"2015","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064555","article-title":"Characterization of influenza vaccine immunogenicity using influenza antigen microarrays","volume":"8","author":"Price","year":"2013","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/msb.2013.15","article-title":"Apoptosis and other immune biomarkers predict influenza vaccine responsiveness","volume":"9","author":"Furman","year":"2013","journal-title":"Mol Syst Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00138","article-title":"Protein microarrays: A new tool for the study of autoantibodies in immunodeficiency","volume":"6","author":"Rosenberg","year":"2015","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M112.026757","article-title":"Autoantibody profiling in multiple sclerosis using arrays of human protein fragments","volume":"12","author":"Ayoglu","year":"2013","journal-title":"Mol Cell Proteomics MCP"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.163150","article-title":"Autoantibodies are highly prevalent in non\u2013SARS-CoV-2 respiratory infections and critical illness","volume":"8","author":"Feng","year":"2023","journal-title":"JCI Insight"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","first-page":"17147","DOI":"10.1038\/s41598-022-22116-0","article-title":"Assessment of variability in the plasma 7k SomaScan proteomics assay","volume":"12","author":"Candia","year":"2022","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1366093","article-title":"Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan","volume":"28","author":"Fujimoto","year":"2018","journal-title":"Mod Rheumatol"},{"key":"B26","unstructured":"R: A Language and Environment for Statistical Computing"},{"key":"B27","unstructured":"RStudio: Integrated Development Environment for R\n          \n          \n          \n          2023"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinforma Oxf Engl"},{"key":"B29","doi-asserted-by":"publisher","first-page":"100158","DOI":"10.1016\/j.xcrm.2020.100158","article-title":"ACCELERATE: A patient-powered natural history study design enabling clinical and therapeutic discoveries in a rare disorder","volume":"1","author":"Pierson","year":"2020","journal-title":"Cell Rep Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.v204.3","article-title":"Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease","volume":"204","author":"Rubenstein","year":"2024","journal-title":"Br J Haematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41577-023-00933-2","article-title":"Anti-cytokine autoantibodies: mechanistic insights and disease associations","volume":"24","author":"Cheng","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.109","article-title":"IL-6-specific autoantibodies among APECED and thymoma patients","volume":"4","author":"K\u00e4rner","year":"2016","journal-title":"Immun Inflammation Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1042\/CS20070272","article-title":"Anti-interleukin-8 autoantibody:interleukin-8 immune complexes in acute lung injury\/acute respiratory distress syndrome","volume":"114","author":"Fudala","year":"2008","journal-title":"Clin Sci Lond Engl 1979"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.2002.1023","article-title":"Oncostatin M production by human dendritic cells in response to bacterial products","volume":"17","author":"Suda","year":"2002","journal-title":"Cytokine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.139.9.2977","article-title":"Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells","volume":"139","author":"Brown","year":"1987","journal-title":"J Immunol Baltim Md 1950"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.24.9739","article-title":"Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells","volume":"83","author":"Zarling","year":"1986","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3780220","article-title":"Oncostatin M production by blood and alveolar neutrophils during acute lung injury","volume":"81","author":"Grenier","year":"2001","journal-title":"Lab Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0410217","article-title":"gp130 at the nexus of inflammation, autoimmunity, and cancer","volume":"88","author":"Silver","year":"2010","journal-title":"J Leukoc Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.29421","article-title":"Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice","volume":"67","author":"Matsuda","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor\u2013neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-019-00934-y","article-title":"Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M","volume":"22","author":"Yu","year":"2019","journal-title":"Gastric Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/stem.1040","article-title":"Induction of osteogenesis in mesenchymal stem cells by activated monocytes\/macrophages depends on oncostatin M signaling","volume":"30","author":"Guihard","year":"2012","journal-title":"Stem Cells Dayt Ohio"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.9.2587.2587","article-title":"Elevated levels of interleukin-1\u03b2 (IL-1\u03b2) and IL-6 in serum and increased production of IL-1\u03b2 mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome","volume":"83","author":"Gherardi","year":"1994","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004016","article-title":"Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease","volume":"5","author":"Pierson","year":"2021","journal-title":"Blood Adv"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/path.v214:2","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J Pathol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00606-1","article-title":"Interferon lambda in inflammation and autoimmune rheumatic diseases","volume":"17","author":"Goel","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1182\/blood-2023-188076","article-title":"A translational approach to identifying and targeting TNF signaling in idiopathic multicentric castleman disease","volume":"142","author":"Mumau","year":"2023","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1528465\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T07:06:04Z","timestamp":1741849564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1528465\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2025.1528465"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1528465","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"article-number":"1528465"}}